Steven Cohen Aprea Therapeutics, Inc. Transaction History

Point72 Asset Management, L.P.

  • $36.6 Billion
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2020

Feb 16, 2021
SELL
$4.92 - $30.67 $624,731 - $3.89 Million
-126,978 Closed
0 $0
Q3 2020

Nov 16, 2020
BUY
$21.66 - $38.86 $2.75 Million - $4.93 Million
126,978 New
126,978 $3.06 Million

Others Institutions Holding APRE

# of Institutions
2
Shares Held
899
Call Options Held
0
Put Options Held
0
View Full List

About Aprea Therapeutics, Inc.

APRE Quotes by TradingView
  • Ticker APRE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Description
  • Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products...
More about APRE
Track Steven Cohen's Portfolio

Track Steven Cohen Portfolio

Follow Steven Cohen (Point72 Asset Management, L.P.) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email